Febuxostat for the chronic management of hyperuricemia in patients with gout

References

• Smith EUR, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24:811–827.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015 Jul 7;11:649–662. doi:10.1038/nrrheum.2015.91. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305–1309.
   PubMed Web of Science ®Google Scholar
• Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Aug;73(8):1470–1476.
   PubMed Web of Science ®Google Scholar
• Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jun 7;pii:S01406736(15)606924.
   Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136–3141.
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Felson DT, Helmick CG, et al National arthritis data workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan;58(1):26–35.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015 Apr;74(4):661–667.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis. 2005 Feb;64(2):267–272.
   PubMed Web of Science ®Google Scholar
• Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271–285.
   PubMed Web of Science ®Google Scholar
• Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology. 2012;51:901–909.
   PubMed Web of Science ®Google Scholar
• Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012 Nov;71(11):1765–1770.
   PubMed Web of Science ®Google Scholar
• Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822–829.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015 Jan;32(1):31–41.
   PubMed Web of Science ®Google Scholar
• Edwards NL, Sundy JS, Forsythe A, et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10–15.
   PubMedGoogle Scholar
• Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014 Nov;10(11):654–661.
   PubMed Web of Science ®Google Scholar
• Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014 May;10(5):271–283.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT) . Ann Rheum Dis. 2006 Oct;65(10):1312–1324.
   PubMed Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447–1461.
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T. Gout. Lancet. 2010 Jan 23;375(9711):318–328.
   PubMed Web of Science ®Google Scholar
• Ovcharova IM, Zasosova IM, Gerchikov LN, et al. Allopurinol, its synthesis and pharmacological activity. Pharm Chem J. 1973 7;11:735–737.
   Google Scholar
• Beara-Lasic L, Pillinger MH, Goldfarb DS. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. Int J Nephrol Renovasc Dis. 2010;3:1–10.
   PubMedGoogle Scholar
• Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;10:CD006077.
   PubMedGoogle Scholar
• Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014 Nov;14(11):CD010457.
   Google Scholar
• Castrejon I, Toledano E, Rosario MP, et al. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015 Jul;35(7):1127–1137.
   PubMed Web of Science ®Google Scholar
• Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164–169.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Dalbeth N, Schlesinger N. Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatol. 2008 10;3(5):421–427.
   Google Scholar
• Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. J Biol Chem. 2003;278:1848–1855.
   PubMed Web of Science ®Google Scholar
• The vision of Febuxostat. Teijin Pharma Limited. Project stories Vol. 01. Japan. 2013. [cited 2015 Aug 23]. Available from: http://www.teijin-pharma.com/project/story01.html
   Google Scholar
• Adenuric. European Medicines Agency. Human medicines. Authorisation details. United Kingdom. 2015. [cited 2015 Aug 19]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000777/human_med_000627.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Adenuric. Summary of product characteristics [Internet]. [cited 2016 Mar 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000777/WC500021812.pdf
   Google Scholar
• Uloric. U. S Food and Drug Administration. Drug approval package. United States. 2009. [cited 2015 Aug 19]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000toc.cfm
   Google Scholar
• The Pharmaceuticals and Medical Devices Agency [Internet]. [cited 2016 Mar 15]. Available from: https://ss.pmda.go.jp/en_all/search.x?q=febuxostat
   Google Scholar
• Uloric. Full prescribing information [Internet]. [cited 2016 Mar 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021856s006lbl.pdf
   Google Scholar
• Perez-Ruiz F, Punzi L. Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations. Eur Rev Med Pharmacol Sci. 2015 May;19(9):1549–1552.
   PubMed Web of Science ®Google Scholar
• Adenuric. Public summary document [Internet]. [cited 2016 Mar 15]. Available from: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-03/Files/febuxostat-psd-march-2015.pdf
   Google Scholar
• Japanese Society of Gout and Nucleic Acid Metabolism. Digest of guideline for the management of hyperuricemia and gout: second edition. Gout and Nucleic Acid Metabolism. 2010;34(1):109–144.
   Google Scholar
• Zyloprim. U.S. Food and Drug Administration. Drugs@FDA. United States. 2015. [cited 2015 Aug 19]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
   Google Scholar
• Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005 Mar 4;76(16):1835–1847.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003 Jan 17;278(3):1848–1855.
   PubMed Web of Science ®Google Scholar
• Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993 Sep 14;241(23):183–188.
   PubMed Web of Science ®Google Scholar
• Khosravan R, Grabowski BA, Wu JT, et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006;45(8):821–841.
   PubMed Web of Science ®Google Scholar
• Khosravan R, Grabowski B, Wu JT, et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008 Mar;65(3):355–363.
   PubMed Web of Science ®Google Scholar
• Zhang M, Di X, Xu L, et al. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med. 2014 Feb;7(2):393–396.
   PubMed Web of Science ®Google Scholar
• Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(89):1119–1122.
   PubMed Web of Science ®Google Scholar
• Khosravan R, Wu JT, Joseph-Ridge N, et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol. 2006 Aug;46(8):855–866.
   PubMed Web of Science ®Google Scholar
• Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496–510.
   PubMed Web of Science ®Google Scholar
• Grabowski B, Khosravan R, Wu JT, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol. 2010 Jul;70(1):57–64.
   PubMed Web of Science ®Google Scholar
• Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(89):1117–1118.
   PubMed Web of Science ®Google Scholar
• Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005 JanFeb;12(1):22–34.
   PubMedGoogle Scholar
• Khosravan R, Grabowski BA, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006 Jan;46(1):88–102.
   PubMed Web of Science ®Google Scholar
• Khosravan R, Kukulka MJ, Wu JT, et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008 Sep;48(9):1014–1024.
   PubMed Web of Science ®Google Scholar
• Doré M, Frenette AJ, Mansour AM, et al. Febuxostat as a novel option to optimize thiopurines’ metabolism in patients with inadequate metabolite levels. Ann Pharmacother. 2014 May;48(5):648–651.
   PubMed Web of Science ®Google Scholar
• Febuxostat. ClincalTrials.gov. United States. 2015. [cited 2015 Aug 23]. Available from: https://clinicaltrials.gov/ct2/results?term=febuxostat&pg=1
   Google Scholar
• Febuxostat. International Clinical Trials Registry Platform. World Health organization. 2015. [cited 2015 Aug 25]. Available from: http://apps.who.int/trialsearch/default.aspx
   Google Scholar
• Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012 Nov;14(11):CD008653.
   Google Scholar
• Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm. 2011 Mar 1;68(5):389–398.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916–923.
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540–1548.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. 2010;12:R63.
   Google Scholar
• Schumacher HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy study. Rheumatology. 2009;48:188–194.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273–1282.
   PubMed Web of Science ®Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S35S43.
   Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44S49.
   Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13–8.
   PubMed Web of Science ®Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S19S26.
   Google Scholar
• Perez-Ruiz F, Chinchilla S, Atxotegi J, et al. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. Rheumatol Int. 2015;35(11):1857–1861.
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014 Jul 10;4(7):e005354.
   PubMed Web of Science ®Google Scholar
• White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012 Jul;164(1):14–20.
   PubMed Web of Science ®Google Scholar
• Richette P, Frazier A, Bardin T. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout. Curr Opin Rheumatol. 2015 Mar;27(2):170–174.
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008 Apr;23(4):1179–1185.
   PubMed Web of Science ®Google Scholar
• Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011 Jan;17(1):7–13.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Kimura K, Itoh S, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014 Jan 16;15:26.
   PubMed Web of Science ®Google Scholar
• Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66:945–950. doi:10.1053/j.ajkd.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Sofue T, Inui M, Hara T, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Drug Des Deliv Ther. 2014 Feb;17(8):245–253.
   Web of Science ®Google Scholar
• Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014 Jun;15(5):453–463.
   PubMed Web of Science ®Google Scholar
• Jutkowitz E, Choi HK, Pizzi LT, et al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014 Nov 4;161(9):617–626.
   PubMed Web of Science ®Google Scholar
• Gandhi PK, Gentry WM, Ma Q, et al. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm. 2015 Feb;21(2):165–175.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Diaz-Torne C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. J Med Econom. 2016;1–7. doi:10.3111/13696998.2016.1149482.
   PubMedGoogle Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77(8):2043–2049.
   PubMed Web of Science ®Google Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol. 2015 Oct;66(4):298–303.
   PubMed Web of Science ®Google Scholar
• Intensive Urate Lowering Therapy With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout (FORWARD). ClinicalTrials.gov. United States. 2015. [cited 2015 Aug 27]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02500641
   Google Scholar